The addition of valproic acid (Depakene) to Dacogen (decitabine) may not improve response rates compared to Dacogen alone in the treatment of myelodysplastic syndromes (MDS) due to valproic acid blocking how Dacogen works.
The findings are from a Phase 2 study conducted by researchers at the M.D. Anderson Cancer Center in Houston and were presented at the 51st annual American Society of Hematology (ASH) meeting and exposition held in New Orleans in December.
Valproic acid…
Myelodysplastic syndromes (MDS) patients show higher and prolonged response rates to Vidaza (azacitidine) in combination with Enbrel (etanercept) than to Vidaza alone, according to a Phase 2 study recently published in the British Journal of Haemotology.
However, the study authors point out that the improved responses were improved marrow responses rather than improvements in blood cell development.
Vidaza, approved by the US Food and Drug Administration in 2004, is a widely used therapy for MDS. However, many MDS patients either do not…
Telik Announces Phase 1 Study Of Telintra And Revlimid Combination Therapy for Myelodysplastic Syndromes Patients — Telik, Inc. announced the start of a Phase 1 clinical trial to test the safety, tolerability, and maximum tolerable dose of Telintra (ezatiostat hydrochloride) in combination with Revlimid (lenalidomide) for myelodysplastic syndromes (MDS) patients. Thirty low to intermediate-1 risk MDS patients will receive Telintra in increasing doses. The drug has recently shown positive results for MDS patients as a single agent,…
The combination therapy of Vidaza (azacitidine) and thalidomide (Thalomid) did not lead to any unexpected side effects in myelodysplastic syndromes (MDS) patients according to a study performed by Australian researchers.
The findings were presented as a poster at the American Society of Hematology meeting and exposition in December 2009.
The Australian study followed results published in 2008 which showed that treating MDS and AML patients with Vidaza and thalidomide was as effective as treating high-risk patients with Vidaza alone (see…